Core Insights - Bel Fuse Inc. has acquired dataMate for $16 million, which is expected to be immediately accretive to Bel's financials with dataMate's annual sales of approximately $18 million and operating margins in line with Bel's corporate averages [1][2] Group 1: Acquisition Details - The acquisition includes $1 million of deferred consideration and was funded through cash on hand and borrowings from the existing revolving credit facility [1][3] - dataMate is a leading solutions provider of advanced ethernet and broadband technologies, which will enhance Bel's portfolio and market position [2][3] Group 2: Strategic Implications - This transaction positions Bel for accelerated growth in high-demand markets such as networking, data centers, industrial automation, smart building management, and broadband deployment [2] - The acquisition expands Bel's US-based manufacturing capabilities, including R&D, sales, and product management functions [3] Group 3: Future Growth Potential - dataMate's ongoing technology development aims to deliver both data and power through a single pair of wires, which could streamline network infrastructure and reduce costs for industrial and smart building applications [2] - The innovative technologies and talented engineering team from dataMate are expected to enhance Bel's leadership in networking solutions and accelerate growth in key markets [3]

Core Insights - Pelthos Therapeutics has acquired the rights to market Xepi (ozenoxacin) cream, a non-fluorinated quinolone antimicrobial, in the US from Biofrontera and Ferrer Internacional, aimed at treating impetigo in both adults and children as young as two months [1][3] - The acquisition was supported by a private financing round that raised $18 million through convertible notes from existing investors, including Ligand Pharmaceuticals and a consortium led by Murchinson [2][5] - Pelthos plans to relaunch Xepi towards the end of 2026, with the product having received FDA approval in 2017 as the first new treatment for impetigo in over a decade [3][4] Financial Details - Pelthos is required to make an upfront payment of $3 million to Biofrontera and $1.2 million to Ferrer, with additional payments contingent on commercial supply levels and future sales [2][3] - The convertible notes will accrue interest at 8.5% annually, with quarterly payments required, maturing on November 6, 2027, unless converted into ordinary shares [4] - Funds raised will also support commercial activities for Zelsuvmi and cover general operational costs, with investors entitled to royalties on US sales of Xepi and milestone payments related to Zelsuvmi's approval in Japan [5] Legal and Advisory Support - Roth Capital Partners advised on the acquisition of Xepi rights, while Latham & Watkins represented Ligand, and Kelley Drye & Warren, along with Morgan, Lewis & Bockius, acted on behalf of Murchinson's investor group [6]